Bracebridge Capital LLC 13D and 13G filings for Clarus Therapeutics Holdings, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-07-06 4:00 pm Unchanged | 2022-07-06 | 13G | Clarus Therapeutics Holdings, Inc. CRXTQ | Bracebridge Capital LLC | 2,002,495 54.000% | 0 (Unchanged) | Filing |
| 2022-02-14 11:34 am Sale | 2021-12-31 | 13G | Clarus Therapeutics Holdings, Inc. CRXTQ | Bracebridge Capital LLC | 2,002,495 8.300% | -227,360 (-10.20%) | Filing |
| 2021-09-17 4:15 pm Purchase | 2021-09-09 | 13G | Clarus Therapeutics Holdings, Inc. CRXTQ | Bracebridge Capital LLC | 2,229,855 10.300% | 2,229,855 (New Position) | Filing |